drugset / Trial / NCT00955916
CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to find out what effects (good and bad) Gleevec® (Imatinib mesylate) combined with chemotherapy has on participants and their acute myeloid leukemia.
Timeline
- Start
- 2009-08
- Primary completion
- 2012-12
- Completion
- 2014-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imatinib | Small molecule | 400 mg | Oral |
| Background | Cladribine | Small molecule | 5 mg/m2 | Intravenous |
| Background | Cytarabine | Small molecule | 300 ug | Subcutaneous |
| Background | Cytarabine | Small molecule | 2 mg/m2 | Intravenous |